Development of an ion-pair reverse-phase liquid chromatographic/tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissue

European Journal of Mass Spectrometry

Volumn 11, Issue 2, 2005, Pages 209-215

  Murphy, Anthony T ^a   Brown Augsburger, Patricia ^a   Yu, Rosie Z ^b   Geary, Richard S ^b   Thibodeaux, Stefan ^a   Ackermann, Bradley L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; HPLC; LC MS MS; Liquid chromatography; Liquid: Liquid extraction; Phosphorothioate oligonucleotides; Tandem mass spectrometry

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; NUCLEOTIDE; PHOSPHATE; PHOSPHORODITHIOIC ACID;

ANIMAL; ARTICLE; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; METABOLISM; METHODOLOGY; MOUSE; VALIDATION STUDY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; LIVER; MICE; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THIONUCLEOTIDES;

EID: 24144481491     PISSN: 14690667     EISSN: None     Source Type: Journal    
DOI: 10.1255/ejms.674     Document Type: Article

References (24)

1. F. Eckstein, "Phosphorothioate oligonucleotides: What is their origin and what is unique about them?", Antisense and Nucleic Acid Drug Dev. 10, 117 (2000).
2. F.R. Khuri and J.M. Kurie, "Antisense approaches enter the clinic", Clin. Cancer Res. 6, 1607 (2000).
3. B.P. Monia, J. Holmlund and F.A. Dorr, "Antisense approaches for the treatment of cancer", Cancer Investigation 18, 635 (2000).
4. S.T. Crooke, "Potential roles of antisense technology in cancer chemotheraphy", Oncogene 19, 6651 (2000).
5. K.T. Flaherty, J.P. Stevenson and P.J. O'Dwyer, "Antisense therapeutics: lessons from early clinical trials", Current Opinion in Oncology 13, 499 (2001).
6. B. Jansen and U. Zangemeister-Wittke, "Antisense therapy for cancer - the time of truth", The Lancet Oncology 3, 672 (2002).
7. S.T. Crooke, "An overview of progress in antisense therapeutics", Antisense and Nucleic Acid Drug Dev. 8, 115 (1998).
8. N.M. Dean, M. Butler, B.P. Monia and M. Manoharan, in Antisense Drug Technology-Principles, Strategies, and Applications, Ed by S.T. Crooke. Marcel Dekker:,New York, p. 622 (2001).
9. C.C. Cunningham, J.T. Holmlund, R.S. Geary, T.J. Kwoh, A. Dorr, J.F. Johnston, B. Monia and J. Nemunaitis, "A Phase I Trial of H- ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma", Cancer 92, 1265 (2001).
10. J.C. Bigelow, L.R. Chrin, L.A. Mathews and J.J. McCormack, "High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids", J. Chromatogr., B: Biomed. Appl. 533, 133 (1990).
11. J. Leeds, M.J. Graham, L. Truong and L.L. Cummins, "Quantitation of phosphorothioate oligonucleotides in human plasma", Anal. Biochem. 235, 36 (1996).
12. M. Maier, H. Fritz, M. Gerster, J. Schewitz and E. Bayer, "Quantitation of phosphorothioate oligonucleotides in human blood plasma using a nanoparticle-based method for solid-phase extraction", Anal. Chem. 70, 2197 (1998).
13. th American Society for Mass Spectrometry, Orlando, FL (2002).
14. st American Society for Mass Spectrometry, Montreal, Canada (2003).
15. S. Chen, M. Qian, J. Brennan and J. Gallo, "Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis", J. Chromatogr. B. 692, 43 (1997).
16. R.H. Griffey, M.J. Greig, H.J. Gaus, K. Liu, D. Monteith, M. Winniman and L.L. Cummins, "Characterization of oligonucleotide metabolism In Vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer", J. Mass Spectrom. 32, 305 (1997).
17. A.S. Cohen, A.J. Bourque. B.H. Wang, D.L. Smisek and A. Belenky, "A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides", Antisense Nucleic Acid Drug Dev. 7, 13 (1997).
18. H. Gaus, S. Owens, M. Winniman, S. Cooper and L.L. Cummins, "On-Line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites", Anal. Chem. 69, 313 (1997).
19. P.F. Grain and J.A. McCloskey, "Applications of mass spectrometry to the characterization of oligonucleotides and nucleic acids", Current Opinion in Biotechnology 9, 25 (1998).
20. C. Huber and H. Oberacher, "Analysis of nucleic acids by on-line liquid chromatography-mass spectrometry", Mass Spectrom. Reviews 20, 310 (2001).
21. A. Apffel, J.A. Chakel, S. Fischer, K. Lichtenwalter and W. Hancock, "Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry", Anal. Chem. 69, 1320 (1997).
22. A. Apffel, J.A. Chakel, S. Fischer, K. Lichtenwalter and W. Hancock, "New procedure for the use of high-performance liquid chromatography- electrospray ionization mass spectrometry for the analysis of nucleotides and oligonucleotides", J. Chromatogr. A 777, 3 (1997).
23. K.J. Fountain, M. Gilar and J.C. Gebler, "Analysis of native and chemically modified oligonucleotides by tandem ion-pair reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry", Rapid Commun. Mass Spectrom. 17, 646 (2003).
24. R.S. Geary, J. Matson and A.A. Levin, "A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue", Anal. Biochem. 274, 241 (1999).